2
|
Araujo GL, Vieira AED, Barreiro EJ, Lima LM, Cardoso CN, Emiliano NF, Martins MT, Souza SS, De Souza AM, Berto C, Costa ML, Campos LM, França FD, Tagliati CA. Toxicological in vitro and subchronic evaluation of LASSBio-596. Food Chem Toxicol 2014; 73:148-56. [PMID: 25139121 DOI: 10.1016/j.fct.2014.07.037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Revised: 07/24/2014] [Accepted: 07/30/2014] [Indexed: 11/30/2022]
Abstract
LASSBio-596, 2-[4-(1,4-tiazinan-4-ylsulfonyl) phenylcarbamoyl] benzoic acid, is an achiral compound containing a subunit carboxylic amide, was capable of preventing induced mechanical and morphological changes in the lungs that commonly caused the onset of asthma. Previous studies to determine the acute toxicity of oral LASSBio-596 at dose of 2000mg/kg caused no deaths in any of the tested animals. To further evaluate the safety of LASSBio-596, in vitro and in vivo tests were carried out. Regarding to in vitro test were used renal, hepatic, pulmonary, cardiac, neurologic and intestinal cell lines. They were evaluated using neutral red (NR) and [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assays. Micronuclei also was performed. Concerning to in vivo was performed subchronic on Wistar rats at doses of 10, 50, and 250mg/kg and zebrafish test. The in vitro tests results showed the safety of LASSBio-596. However, subchronic toxicity study results revealed changes in the blood parameters of amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose and creatine kinase (CK) which is used for cardiotoxicity evaluation, although, did not identify any histopathological alterations. However, zebrafish test demonstrated cardiac damage. It was impossible to estimate the no-observed-adverse-effect-levels and lowest observed-adverse-effect level due to the presence of cardiotoxicity in all tested doses.
Collapse
Affiliation(s)
- G L Araujo
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil.; Laboratório de Toxicologia Experimental, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte-MG, 31270-901, Brazil
| | - A E D Vieira
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil.; Laboratório de Toxicologia Experimental, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte-MG, 31270-901, Brazil
| | - E J Barreiro
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil
| | - L M Lima
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil
| | - C N Cardoso
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil.; Laboratório de Toxicologia Experimental, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte-MG, 31270-901, Brazil
| | - N F Emiliano
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil.; Laboratório de Toxicologia Experimental, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte-MG, 31270-901, Brazil
| | - M T Martins
- Laboratório de Toxicologia Experimental, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte-MG, 31270-901, Brazil
| | - S S Souza
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil.; Laboratório de Toxicologia Experimental, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte-MG, 31270-901, Brazil
| | - A M De Souza
- Laboratório de Imagem Biológica, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil
| | - C Berto
- Laboratório de Imagem Biológica, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil
| | - M L Costa
- Laboratório de Imagem Biológica, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil
| | - L M Campos
- Laboratório de Imagem Biológica, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil
| | - F D França
- Laboratório de Imagem Biológica, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil
| | - C A Tagliati
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR; (1)), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, 68006, Rio de Janeiro-RJ, 21941-971, Brazil.; Laboratório de Toxicologia Experimental, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte-MG, 31270-901, Brazil.
| |
Collapse
|
5
|
Pazetti R, Pego-Fernandes PM, Ranzani OT, Parra ER, Lorenzi-Filho G, Jatene FB. Cyclosporin A reduces airway mucus secretion and mucociliary clearance in rats. Clinics (Sao Paulo) 2007; 62:345-52. [PMID: 17589677 DOI: 10.1590/s1807-59322007000300021] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2006] [Accepted: 02/23/2007] [Indexed: 11/22/2022] Open
Abstract
PURPOSE To assay the effects of cyclosporin A on mucus secretion from goblet cells and on mucociliary transport in situ in rats. METHODS Twenty-one male Wistar rats were assigned to 3 groups: control (n = 5), saline (n = 8), and cyclosporin A (n = 8). After 30 days of drug therapy, the rats were killed, and the lungs were removed from the thoracic cavity. Mucus samples were collected, and the transport rate was evaluated in vitro using a bullfrog palate model. Mucociliary transport was timed in situ by direct view of particles trapped on the mucus moving across the respiratory tract. Finally, the amount of stored mucins in the goblet cells of the respiratory epithelium was measured. RESULTS Drug dosage measurements showed that cyclosporine blood concentration at the moment the rats were killed was 1246.57 +/- 563.88 ng/mL. The in vitro transport rate was significantly lower (P < .001) in the cyclosporin A-treated group. Also, the in-situ mucociliary transport rate was decreased in all cyclosporin A-treated animals when compared to the saline group (P = .02). Mucus quantity measurements showed a significant decrease on both acid (P = .01) and neutral (P = .02) mucus production from goblet cells in the animals submitted to cyclosporin A therapy. The correlation between the percentage of total mucus and in vitro transport rate was positive and significant (r = 0.706, P < .001), as was the correlation between the percentage of total mucus and the in situ mucociliary transport rate (r = 0.688, P = .001). CONCLUSION This study shows that cyclosporin A plays an important role in the impairment of the mucociliary clearance in rats by reducing both acid and neutral mucus production from goblet cells and causing a decrease in the mucociliary transport velocity.
Collapse
Affiliation(s)
- Rogerio Pazetti
- Thoracic Surgery Service, Hospital das Clinicas, University of Sao Paulo, Sao Paulo, SP, Brazil.
| | | | | | | | | | | |
Collapse
|